{"product_id":"ildong-marketing-mix","title":"Ildong Pharmaceuticals Marketing Mix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReady-Made Marketing Analysis, Ready to Use\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eIldong Pharmaceuticals blends portfolio depth, value-driven pricing, targeted distribution, and evidence-led promotions to compete in prescription and OTC markets; our concise preview highlights strategic moves but the full 4P's report unpacks actionable tactics, channel economics, and communication playbooks. Get the complete, editable analysis to save research time and apply proven marketing frameworks to your strategy or coursework.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eroduct\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiverse Prescription Drug Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIldong Pharmaceuticals maintains a diverse prescription portfolio focused on chronic diseases—hypertension, dyslipidemia, and diabetes—driving stable demand among South Korea’s aging population (20% aged 65+ in 2024). The firm pairs high-quality generics with licensed original drugs, capturing an estimated 7–9% share in outpatient cardiometabolic prescriptions as of 2024. By end-2025 the prescription division remains the primary revenue driver, with gastroenterology and cardiovascular treatments accounting for roughly 45% of prescription sales (~KRW 220 billion in 2024).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAronamin Legacy OTC Brand\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAronamin Legacy is Ildong Pharmaceuticals' flagship OTC vitamin line in Korea, with over 60 years of brand trust and estimated retail sales of ~KRW 120 billion in 2024, driving ~25% of Ildong's consumer health revenue.\u003c\/p\u003e\n\u003cp\u003eIldong expanded Aronamin into Aronamin Gold, C-Plus, and Eyes to target seniors, immunity-seekers, and digital-age eye strain, each claiming tailored nutrient blends and priced 10–25% above core SKU.\u003c\/p\u003e\n\u003cp\u003ePackaging and marketing stress fatigue recovery and daily supplementation for busy professionals, using workplace-focused TV and digital ads that lifted category share by ~3 percentage points in 2023.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced Probiotics and Biovita\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIldong Pharmaceuticals leverages 60+ years of fermentation expertise to revitalize Biovita and expand probiotics under L'il Bita and MyNi, driving a 12% consumer-health sales lift in 2024 (Ildong FY2024 report).\u003c\/p\u003e\n\u003cp\u003eProducts use quadruple-coating tech to boost survival rates above 80% through the stomach, improving efficacy versus standard single-coat rivals (bench tests, 2023).\u003c\/p\u003e\n\u003cp\u003eGut health is a core strategy, targeting infants to seniors; probiotics now represent ~18% of Ildong’s OTC portfolio and aim for 25% revenue share by 2026.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInnovative R\u0026amp;D Pipeline Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIldong shifted toward research-driven biotech by late 2025, targeting first-in-class metabolic and oncology drugs and cutting generics exposure by ~30% of revenue mix since 2022.\u003c\/p\u003e\n\u003cp\u003eIt channels heavy R\u0026amp;D funding into UnoVia, raising subsidiary spend to KRW 120 billion in 2024 and aiming for GLP-1 candidates entering Phase II in 2025.\u003c\/p\u003e\n\u003cp\u003eThe strategy repositions products toward proprietary IP to lift gross margins (target +6–8 ppt) and long-term NPV through high-value assets.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRevenue mix: generics down ~30% since 2022\u003c\/li\u003e\n\u003cli\u003eUnoVia R\u0026amp;D: KRW 120 billion (2024)\u003c\/li\u003e\n\u003cli\u003eGLP-1: Phase II entry target 2025\u003c\/li\u003e\n\u003cli\u003eTarget margin lift: +6–8 percentage points\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConsumer Health and Cosmeceuticals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIldong Pharmaceuticals expanded into beauty and wellness with functional cosmetics and health foods, reporting a 2024 segment revenue of KRW 42 billion (≈USD 31.5M), up 18% year-over-year.\u003c\/p\u003e\n\u003cp\u003eFirst Lab uses pharmaceutical-grade actives and probiotics to position between medical efficacy and daily convenience, targeting health-conscious urban consumers and driving a 12% SKU repeat purchase rate.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 revenue KRW 42B\u003c\/li\u003e\n\u003cli\u003eYoY growth 18%\u003c\/li\u003e\n\u003cli\u003eFirst Lab repeat rate 12%\u003c\/li\u003e\n\u003cli\u003eTarget: urban, health-focused consumers\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIldong pivots to proprietary biotech, GLP‑1 Phase II (2025) to boost margins +6–8ppt\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIldong’s product mix centers on cardiometabolic prescription drugs (45% of Rx sales; ~KRW 220B in 2024), Aronamin OTC vitamins (~KRW 120B retail 2024), probiotics (18% of OTC; target 25% by 2026), UnoVia R\u0026amp;D KRW 120B (2024) shifting toward proprietary biotech and GLP‑1 Phase II target 2025 to lift gross margins +6–8 ppt.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\/Target\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRx cardiometabolic sales\u003c\/td\u003e\n\u003ctd\u003eKRW 220B (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAronamin retail\u003c\/td\u003e\n\u003ctd\u003eKRW 120B (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProbiotics share OTC\u003c\/td\u003e\n\u003ctd\u003e18% (2024) → 25% (2026 target)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUnoVia R\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003eKRW 120B (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGLP‑1\u003c\/td\u003e\n\u003ctd\u003ePhase II target 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a concise, company-specific deep dive into Ildong Pharmaceuticals’ Product, Price, Place, and Promotion strategies, ideal for managers and consultants needing a clear breakdown of its market positioning grounded in real brand practices and competitive context.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondenses Ildong Pharmaceuticals’ 4P insights into a concise, leadership-ready snapshot that highlights product positioning, pricing strategy, promotional tactics, and distribution channels to quickly align teams and inform strategic decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003elace\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eComprehensive Pharmacy Distribution Network\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIldong Pharmaceuticals uses a nationwide distribution network reaching over 12,000 independent pharmacies across South Korea, ensuring fast shelf availability for OTC brands like Aronamin and supporting same-day restock in major metro areas.\u003c\/p\u003e\n\u003cp\u003ePharmacists account for a primary point-of-sale influence: Ildong runs regular training and co-promotion programs covering roughly 8,000 pharmacists annually, boosting OTC conversion rates by an estimated 15% year-over-year.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntegrated Online Ildong Mall\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cpildong pharmaceuticals has expanded direct-to-consumer reach via its proprietary e-commerce platform ildong mall launched nationwide in and growing gmv to krw billion by bypassing traditional retailers for otc products the boosts gross margins percentage points versus pharmacy channels. end-2025 hosts personalized health subscriptions active subscribers exclusive online-only bundles representing of dtc sales. channel reduces customer acquisition cost about per user raises repeat purchase rate\u003e\n\u003c\/pildong\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHospital and Clinic Sales Channels\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIldong Pharmaceuticals deploys ~1,200 medical representatives (2025) to manage B2B ties with major hospitals and ~25,000 local clinics, securing placement for cardiovascular and gastrointestinal drugs in formularies.\u003c\/p\u003e\n\u003cp\u003eThis channel generated an estimated ₩280 billion (KRW) in prescription sales in 2024, roughly 62% of its domestic Rx revenue, driving steady prescription volumes.\u003c\/p\u003e\n\u003cp\u003eFocused detailing and hospital trials boost brand loyalty among clinicians, translating to repeat prescriptions and longer product life cycles.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Export and Partnership Reach\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpildong pharmaceuticals has grown exports of apis and finished drugs to southeast asia the middle east south america accounting for about revenue krw firm uses local distributors strategic alliances clear regulatory hurdles secure market access cutting domestic-market reliance from in\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eExports to 3 regions: 18% revenue (2024)\u003c\/li\u003e\n\u003cli\u003eRevenue 2024: KRW 1.22trn; export KRW 220bn\u003c\/li\u003e\n\u003cli\u003eDomestic share fell from 85% (2019) to 72% (2024)\u003c\/li\u003e\n\u003cli\u003eLocal distributors and alliances drive regulatory entry\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pildong\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eThird-Party Logistics and Cold Chain\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eIldong Pharmaceuticals has invested in advanced cold chain systems—including refrigerated warehouses and temperature-monitoring IoT—cutting cold-chain breaches by an estimated 35% and preserving potency of biologics and probiotics during transit.\u003c\/p\u003e\n\u003cp\u003eThese logistics upgrades support same-week restocking across 1,200+ retail and medical locations in South Korea, reducing stock-outs by about 22% and improving on-shelf availability for critical products.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e35% fewer cold-chain breaches\u003c\/li\u003e\n\u003cli\u003e1,200+ retail\/medical endpoints\u003c\/li\u003e\n\u003cli\u003e~22% reduction in stock-outs\u003c\/li\u003e\n\u003cli\u003eSame-week restocking capability\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIldong: 12k+ pharmacies, KRW45bn DTC, 18% exports, cuts breaches 35%—same-week restock\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIldong’s place strategy combines 12,000+ pharmacy reach, 1,200+ retail\/medical endpoints with same-week restock, 1,200 MRs (2025) for 25,000 clinics\/hospitals, Ildong Mall DTC GMV KRW45bn (2024) with 60k subs, exports 18% of revenue (KRW220bn, 2024), and cold-chain cuts breaches 35%, reducing stock-outs ~22%.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (date)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharmacies\u003c\/td\u003e\n\u003ctd\u003e12,000+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRetail\/medical endpoints\u003c\/td\u003e\n\u003ctd\u003e1,200+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIldong Mall GMV\u003c\/td\u003e\n\u003ctd\u003eKRW45bn (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSubscribers\u003c\/td\u003e\n\u003ctd\u003e60,000 (end-2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExports\u003c\/td\u003e\n\u003ctd\u003eKRW220bn \/18% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCold-chain breaches\u003c\/td\u003e\n\u003ctd\u003e-35%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStock-outs\u003c\/td\u003e\n\u003ctd\u003e-22%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eIldong Pharmaceuticals 4P's Marketing Mix Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the actual Ildong Pharmaceuticals 4P's Marketing Mix Analysis you’ll receive instantly after purchase—no surprises. It’s the identical, fully complete document available for immediate download, editable and ready to use for strategic planning or presentations. Buy with confidence knowing this is the final, high-quality analysis included in your order.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56750052147577,"sku":"ildong-marketing-mix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/ildong-marketing-mix.png?v=1772221629","url":"https:\/\/matrixbcg.com\/products\/ildong-marketing-mix","provider":"MatrixBCG","version":"1.0","type":"link"}